Search

Author/Creator Chang, Chai-Ni

1. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Issue 9980 (9th May 2015)

Authors:
Hillmen, Peter; Robak, Tadeusz; Janssens, Ann; Babu, K Govind; Kloczko, Janusz; Grosicki, Sebastian; Doubek, Michael; Panagiotidis, Panagiotis; Kimby, Eva; Schuh, Anna; Pettitt, Andrew R; Boyd, Thomas; Montillo, Marco; Gupta, Ira V; Wright, Oliver; Dixon, Iestyn; Carey, Jodi L; Chang, Chai-Ni; Li...
Journal:
Lancet
Issue:
Volume 385:Issue 9980(2015)
Page Start:
1873
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. (2nd October 2016)

Authors:
Hillmen, Peter; Janssens, Ann; Babu, K. Govind; Kloczko, Janusz; Grosicki, Sebastian; Manson, Stephanie; McKeown, Astrid; Gupta, Ira; Chang, Chai-Ni; Offner, Fritz
Journal:
Acta oncologica
Issue:
Volume 55:Number 9-10(2016)
Page Start:
1115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Issue 7 (3rd July 2017)

Authors:
Robak, Tadeusz; Warzocha, Krzysztof; Govind Babu, K.; Kulyaba, Yaroslav; Kuliczkowski, Kazimierz; Abdulkadyrov, Kudrat; Loscertales, Javier; Kryachok, Iryna; Kłoczko, Janusz; Rekhtman, Grygoriy; Homenda, Wojciech; Błoński, Jerzy Z.; McKeown, Astrid; Chang, Chai-Ni; Bal, Vasudha; Lisby, Steen; Gup...
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 7(2017)
Page Start:
1598
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Issue 5 (4th May 2017)

Authors:
Robak, Tadeusz; Warzocha, Krzysztof; Govind Babu, K.; Kulyaba, Yaroslav; Kuliczkowski, Kazimierz; Abdulkadyrov, Kudrat; Loscertales, Javier; Kryachok, Iryna; Kłoczko, Janusz; Rekhtman, Grygoriy; Homenda, Wojciech; Błoński, Jerzy Z.; McKeown, Astrid; Gorczyca, Michele M.; Carey, Jodi L.; Chang, Ch...
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 5(2017)
Page Start:
1084
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Issue 9 (1st September 2016)

Authors:
Österborg, Anders; Udvardy, Miklós; Zaritskey, Andrey; Andersson, Per-Ola; Grosicki, Sebastian; Mazur, Grzegorz; Kaplan, Polina; Steurer, Michael; Schuh, Anna; Montillo, Marco; Kryachok, Iryna; Middeke, Jan Moritz; Kulyaba, Yaroslav; Rekhtman, Grygoriy; Gorczyca, Michele; Daly, Siobhan; Chang, Ch...
Journal:
Leukemia & lymphoma
Issue:
Volume 57:Issue 9(2016:Sep.)
Page Start:
2037
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗